ArticleCancer research2021
Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer.
Open access · hybridAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 7 pooled it
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 7 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.Advances in therapy · 2025Pooled it
- Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- Pooled it
- COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Journal for immunotherapy of cancer · 2023Pooled it
- Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.Blood cancer journal · 2022Pooled it
- A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.International immunopharmacology · 2022Pooled it
- Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.Blood cancer journal · 2022Pooled it
- mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation.Frontiers in pharmacology · 2026Review
- Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses.Human vaccines & immunotherapeutics · 2025Article
- Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies.British journal of haematology · 2025Article
- In the time of COVID-19: challenges, successes, and lessons learned from studies in cancer patients.Journal of the National Cancer Institute · 2025Article
- Circulating SARS-CoV-2 spike IgG antibody responses in cancer patients following multiple COVID-19 vaccination boosters.Frontiers in immunology · 2025Article
- Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections.Clinical lung cancer · 2024Article
- Article
- Review
- Article
- Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment.Journal of functional biomaterials · 2024Review
- Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics.Heliyon · 2024Review
- Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile.Journal for immunotherapy of cancer · 2024Observational
- mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 6 institutions in 2 countries.
Jane C FigueiredoDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California. Jane.Figueiredo@cshs.org Karen.Reckamp@cshs.org Akil.Merchant@cshs.org.ORCID 0000-0001-8040-3341
Noah M MerinDivision of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Omid HamidThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California.ORCID 0000-0002-8238-4655
So Yung ChoiBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California.
Tucker LemosDivision of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Wendy CozenDivision of Hematology/Oncology, Department of Medicine, Department of Pathology, School of Medicine, University of California Irvine, Orange, California.ORCID 0000-0003-3415-8247
Nathalie NguyenDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
Laurel J FinsterDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0002-5974-8860
Joslyn FoleyDivision of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Justin DarrahDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
Jun GongDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
Ronald PaquetteDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
Alain C MitaDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
Robert VescioDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
Inderjit MehmiThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California.ORCID 0000-0002-2253-2206
Reva BashoDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
Warren G TourtellotteDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Carissa A HuynhDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Gil Y MelmedF. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California.
Jonathan BraunF. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California.ORCID 0000-0003-1646-2974
Dermot P B McGovernF. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California.
Emebet MengeshaF. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California.ORCID 0000-0001-7830-1557
Greg BotwinF. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California.
John C ProstkoAbbott Diagnostics, Lake Forest, Illinois.
Edwin C FriasAbbott Diagnostics, Lake Forest, Illinois.
James L StewartAbbott Diagnostics, Lake Forest, Illinois.
Sandy JoungDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Jennifer Van EykDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Joseph E EbingerDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Susan ChengDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Kimia SobhaniDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Karen L Reckamp *Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California. Jane.Figueiredo@cshs.org Karen.Reckamp@cshs.org Akil.Merchant@cshs.org.ORCID 0000-0002-9213-0325
Akil Merchant *Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. Jane.Figueiredo@cshs.org Karen.Reckamp@cshs.org Akil.Merchant@cshs.org.
Cedars-Sinai Medical Center · USPatanjali Research Foundation · INCedars-Sinai Smidt Heart Institute · USLake Forest College · USAngeles Clinic and Research Institute · USUniversity of California, Irvine · US
Funding
Using polygenic scores to enhance both variant discovery, and understanding of functional consequences of genetic variation in IBD.P01DK046763 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI TARGAN, STEPHAN R. · 1992 to 2020
$31.1MUtilizing the Phenomics of IBD to Enhance Gene DiscoveryU01DK062413 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI Dermot Patrick McGovern · 2002 to 2026
$12.2MDiversity and Determinants of the Immune-Inflammatory Response to SARS-CoV-2U54CA260591 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FIGUEIREDO, JANE C., KARIN, MICHAEL · 2020 to 2024
$9.1MElp1 function in Familial DysautonomiaR01NS095894 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI TOURTELLOTTE, WARREN G · 2016 to 2019
$1.6MImplementation Science to Improve Cardiovascular Health: Leveraging EHR Systems to Advance Care of Resistant HypertensionK23HL153888 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI EBINGER, JOSEPH · 2020 to 2024
$929kMentoring and Research in Mouse PathobiologyK26OD010945 · OD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI TOURTELLOTTE, WARREN G · 2012 to 2014
$471kMentoring and Research in Mouse PathobiologyK26RR026099 · NCRR · NORTHWESTERN UNIVERSITY AT CHICAGO · PI TOURTELLOTTE, WARREN G · 2010 to 2011
$317kNCI NIH HHS U54 CA260591NCRR NIH HHS K26 RR026099NHLBI NIH HHS K23 HL153888NIDDK NIH HHS P01 DK046763NIDDK NIH HHS U01 DK062413NIH HHS K26 OD010945NINDS NIH HHS R01 NS095894
Abstract
Longitudinal studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-induced immune responses in patients with cancer are needed to optimize clinical care. In a prospective cohort study of 366 (291 vaccinated) patients, we measured antibody levels [anti-spike (IgG-(S-RBD) and anti-nucleocapsid immunoglobulin] at three time points. Antibody level trajectories and frequency of breakthrough infections were evaluated by tumor type and timing of treatment relative to vaccination. IgG-(S-RBD) at peak response (median = 42 days after dose 2) was higher (
Indexed as
2019-nCoV Vaccine mRNA-1273BNT162 VaccineImmunity, HumoralSARS-CoV-2AdultAgedAntibodies, ViralCOVID-19FemaleHumansImmunization ProgramsImmunoglobulin GLongitudinal StudiesMaleMiddle AgedNeoplasms2019-nCoV Vaccine mRNA-1273Antibodies, ViralBNT162 VaccineImmunoglobulin G
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.